Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck & Co.
Pharma
Novartis CEO shrugs off oral PCSK9 threat amid Q2 growth
Novartis' CEO remains unfazed by the threat of Merck's newly approved oral PCSK9 inhibitor, Lipfendra, to his company's injectable Leqvio.
Angus Liu
Jul 21, 2026 10:36am
Gilead, Merck phase 3 data back first weekly HIV pill
Jul 21, 2026 10:00am
GSK-Hansoh, Merck-Kelun, AZ-Dizal—Fierce Pharma Asia
Jul 17, 2026 9:38am
Merck touts Keytruda front-line win in endometrial cancer subtype
Jul 15, 2026 3:33pm
Kelun's sac-TMT win offers blueprint for Merck's global gap
Jul 15, 2026 10:20am
FDA expands Padcev-Keytruda combo to more MIBC patients
Jul 10, 2026 1:10pm
